Brought to you by 
Merck Invests In NGM, Gets Options to License New Biologics; Later Amends Agreement
21 Dec 2022
Executive Summary
Merck & Co. Inc. paid $94mm up front and $106mm for a 15% equity stake in NGM Biopharmaceuticals Inc., in exchange for the chance to further develop and sell the private biotech’s preclinical biologic therapies for multiple indications.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Technologies
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Merck Invests In NGM, Gets Options to License New Biologics; Later Amends Agreement
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice